CTX310 and the Future of Gene Editing for Lipid Disorders

Cardiac Consult: A Cleveland Clinic Podcast for Healthcare Professionals by Cleveland Clinic Heart & Vascular Institute

Steven Nissen, MD, and Luke Laffin, MD, discuss one-year follow-up data for CTX310, a CRISPR-Cas9 gene-editing therapy targeting ANGPTL3 to treat lipid disorders. They review the sustained reductions in LDL cholesterol a...View more